Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer. <a title= "Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’" href="http://bit.ly/Lindsay-podcast-WCLC-2019" target="_blank" rel= "noopener">Find more on Medicine Matters oncology</a> <a title="WCLC 2019 hub" href="http://bit.ly/WCLC-2019-coverage" target="_blank" rel="noopener">More from WCLC 2019</a>

Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation – in patients with locally advanced or metastatic non-small-cell lung cancer. Find more on Medicine Matters oncology More from WCLC 2019

Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the&nbsp;KRAS&nbsp;G12C mutation –&nbsp; in patients with locally advanced or metastatic non-small-cell lung cancer. <a title="Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’" href="http://bit.ly/Lindsay-podcast-WCLC-2019" rel="noopener noreferrer">Find more on Medicine Matters oncology</a> <a title="WCLC 2019 hub" href="http://bit.ly/WCLC-2019-coverage" rel="noopener noreferrer">More from WCLC 2019</a>

Share Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)

Sign up to save your podcasts

Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)

Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)